Association between chronic pain medications and the severity and mortality of COVID-19 : Study protocol for a case-population study
Serrano Afonso, Ancor (Institut d'Investigació Biomèdica de Bellvitge)
Pérez Hernández, Concepción (Hospital Universitario de la Princesa (Madrid))
Ochoa Mazarro, Dolores (Hospital Universitario de la Princesa (Madrid))
Román Martínez, Manuel (Hospital Universitario de la Princesa (Madrid))
Failde Martínez, Inmaculada (Universidad de Cádiz)
Montes Pérez, Antonio (Institut Hospital del Mar d'Investigacions Mèdiques)
López Pais, P. (Complejo Hospitalario Universitario de Santiago de Compostela)
Cánovas Martínez, Luz Noguero (Complejo Hospitalario Universitario de Ourense)
Revuelta Rizo, Miren (Institut d'Investigació Biomèdica Sant Pau)
Padilla-del-Rey, María-Luz (Complejo Hospitalario Universitario de Cartagena)
Peiró Perió, Ana (Hospital General Universitario de Alicante (Alacant, País Valencià))
Aberasturi Fueyo, Teresa (Hospital Comarcal Alt Penedes)
Margarit-Ferri, César (Hospital General Universitario de Alicante (Alacant, País Valencià))
Rojo Rodríguez, Elena (Hospital Universitario de la Princesa (Madrid))
Mendiola de La Osa, Agustín (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Muñoz Martinez, Manuel José (Hospital Universitario de la Princesa (Madrid))
Domínguez Bronchal, María Jesús (Complejo Hospitalario Universitario de Toledo)
Herrero Trujillano, Manuel (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Cid Calzada, José (Complejo Hospitalario Universitario de Toledo)
Fabregat-Cid, Gustavo (Hospital General Universitario de Valencia)
Hernández-Cádiz, María José (Hospital General Universitario de Valencia)
Mareque Ortega, Manuel (Complejo Hospitalario Universitario de Toledo)
Gómez-Caro Álvarez Palencia, Leticia (Complejo Hospitalario Universitario de Toledo)
Mayoral Rojals, Víctor (Institut d'Investigació Biomèdica de Bellvitge)

Fecha:	2021
Resumen:	In patients with coronavirus disease 2019 (COVID-19) infection, common drugs may exacerbate symptoms and negatively impact outcomes. However, the role of chronic medications on COVID-19 effects remains poorly understood. We hypothesized that certain chronic pain medications would influence outcomes in patients with COVID-19. The main aim is to assess the effect of these medications on the course of the disease in COVID-19 patients. Secondary aims are to compare disease severity and outcomes in patients with COVID-19 receiving chronic treatment with analgesics or other medications versus untreated patients and to determine prevalence of chronic pain medications in specific subgroups of hospitalized patients for COVID-19. Multicenter case-population study in 15 care centers for patients ≥18years of age diagnosed and hospitalized with COVID-19. Controls will include patients treated at participating centers for chronic pain during the six-month period prior to March 15th, 2020. Each case will be age- and sex-matched to 10 controls. Patients will be grouped according to disease severity criteria. The primary outcome measures in patients admitted for COVID-19 will be:1. statistical association between chronic pain medication and disease severity;2. association between chronic pain treatment and survival. Secondary outcome measures include:1. prevalence of chronic pain medications in patients with COVID-19 by age and sex;2. prevalence of chronic pain medications in patients with COVID-19 vs controls. Patients and controls will be paired by age, sex, and geographic residence. Odds ratios with 95% confidence intervals will be calculated to determine the association between each drug and clinical status. Univariate and multivariate analyses will be performed. This is a study protocol. Data is actually being gathered and results are yet not achieved. There is no numerical data presented, so the conclusions cannot be considered solid at this point. Pain medications are likely to influence severity of COVID-19 and patient survival. Identifying those medications that are most closely associated with severe COVID-19 will provide clinicians with valuable data to guide treatment and reduce mortality rates and the long-term sequelae of the disease.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Analgesics ; Chronic pain ; Coronavirus disease 2019 ; Glucocorticoids ; Non-steroidal anti-inflammatory drugs ; Opioids
Publicado en:	Medicine, Vol. 100 Núm. 30 (July 2021) , p. E26725, ISSN 1536-5964

DOI: 10.1097/MD.0000000000026725
PMID: 34397708

7 p, 239.1 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados